Flputnam Investment Management Co. Buys 17,300 Shares of Bristol Myers Squibb Company $BMY

Flputnam Investment Management Co. grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 9.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 203,601 shares of the biopharmaceutical company’s stock after acquiring an additional 17,300 shares during the quarter. Flputnam Investment Management Co.’s holdings in Bristol Myers Squibb were worth $10,982,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Poinciana Advisors Group LLC acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $606,000. Integrity Alliance LLC. raised its position in shares of Bristol Myers Squibb by 314.0% during the fourth quarter. Integrity Alliance LLC. now owns 37,376 shares of the biopharmaceutical company’s stock worth $2,016,000 after purchasing an additional 28,348 shares during the period. Arvest Bank Trust Division raised its position in shares of Bristol Myers Squibb by 7.2% during the fourth quarter. Arvest Bank Trust Division now owns 13,053 shares of the biopharmaceutical company’s stock worth $704,000 after purchasing an additional 875 shares during the period. Cary Street Partners Investment Advisory LLC raised its position in shares of Bristol Myers Squibb by 19.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 5,582 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 901 shares during the period. Finally, Smithfield Trust Co raised its position in shares of Bristol Myers Squibb by 18.4% during the fourth quarter. Smithfield Trust Co now owns 18,319 shares of the biopharmaceutical company’s stock worth $990,000 after purchasing an additional 2,841 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 2.1%

BMY stock opened at $58.19 on Wednesday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business has a 50 day moving average price of $58.46 and a two-hundred day moving average price of $56.11. The company has a market cap of $118.83 billion, a price-to-earnings ratio of 16.35, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BMY. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. HSBC increased their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. UBS Group reiterated a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, March 6th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $61.31.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.